The FDA’s approval of the first therapy to treat Alzheimer’s Disease in over twenty years brought attention to a not-yet-convened debate of U.S. health care costs and spending, innovation, and return-on-the-investment (as well as “for whom” do the returns accrue). In my latest post for Medecision, I explore different angles on the Aduhelm and Alzheimer’s… Read More »
[embedded content] (Transcript) [CRAIG MACE Operational Supervisor, Regional Transport] Given the situation with the pipeline. We had a need, a critical need for gasoline and diesel fuel due to the shortage in the gas stations here in western North Carolina to be able to perform our operation of caring for and transporting patients. [BRIAN LEDERBRAND,… Read More »
It’s been a rough and difficult year for us. Separation, desperation, depression, illness, and death are scattered among the months that have passed by. Hope, for the longest time, seemed non-existent. The COVID virus gave the world a “sucker punch,” leveling us all to the ground. Positivity test rates sky-rocketed, death rates at unacceptable levels.… Read More »
There are ethnic disparities in relation to two key indicators of the quality of HIV care, but there are no differences in viral suppression within a year of starting treatment, Dr Rageshri Dhairyawan told the virtual British HIV Association (BHIVA) conference yesterday. Although the differences are not large, dealing with them is necessary if the… Read More »